NewsEli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand Posted on October 29, 2026 by budd87309@gmail.com Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter. budd87309@gmail.com Restaurant Brands reports mixed results as Burger King’s U.S. turnaround shows signs of success Alphabet earnings miss reflects first real sign that AI is taking a bite out of search
